Lung lesions these days are typically found and mapped via CT scans, that provide an imaging resolution sufficient to see them. During biopsies and surgeries, fluoroscopes are used, but their lower image quality makes it usually impossible to actually see whether you’re excising the correct tissue’s margins. Body Vision Medical, with offices in Israel and New York City, just won FDA clearance for its LungVision system, which consists of a navigation catheter and tracking technology that superimposes pre-procedural imaging data, the intraoperative 2D imaging from the fluoroscope, and the pathway of the catheter to help guide exactly to its target.
The company promises intuitive integration of its technology with existing operating room equipment, which shouldn’t affect the flow of the established procedures
Results of the first in-human study of the LungVision will be discussed in the coming days by Dr Sean Stoy of the University of Chicago Medical Center during the American Thoracic Society meeting in Washington, D.C.
Product page: LungVision…
Via: Body Vision Medical…